Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

115.63
+0.19000.16%
Volume:528.84K
Turnover:61.24M
Market Cap:144.00B
PE:304.29
High:116.30
Open:115.46
Low:115.22
Close:115.44
Loading ...

Gilead Sciences: Strong Momentum and Promising Future with New HIV Drug Launch Justifies Buy Rating

TIPRANKS
·
03 Mar

U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund

Reuters
·
03 Mar

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.
·
01 Mar

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Zacks
·
01 Mar

Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating

MT Newswires Live
·
01 Mar

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Zacks
·
28 Feb

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 Feb

Salesforce Stock Falls On Weak Revenue Outlook Amid Artificial Intelligence Push

Blockhead
·
27 Feb

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Zacks
·
26 Feb

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks
·
26 Feb

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Zacks
·
26 Feb

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Zacks
·
26 Feb

Healthcare Stocks Should Be Hurting. How the Sector Became This Year's Top Performer. -- Barrons.com

Dow Jones
·
26 Feb

Morgan Stanley sees FDA approval of GILD's Lenacapavir

Investing.com
·
26 Feb

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Zacks
·
26 Feb

Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU

MT Newswires Live
·
24 Feb